ENvue Medical, Inc. Annual Report - How They Did This Year

I’ve put together this guide to help you understand how ENvue Medical performed this year. My goal is to turn complex financial filings into plain English so you can decide if this company fits your investment goals.

1. What does this company do and how did they perform?

ENvue Medical (formerly NanoVibronix) creates non-invasive, ultrasound-based medical devices like UroShield and PainShield. The company is currently undergoing a major transformation after its February 2025 merger with ENvue Medical Holdings. This move shifted the business from its older ultrasound products toward a broader portfolio of medical technology and customer lists. Think of this as a "reset." The company is essentially a startup working to combine these new assets into a single business focused on growth.

2. Financial performance: The numbers that matter

The company is in a growth phase and reported a loss of about $8.2 million for the 2025 fiscal year. Revenue was modest at roughly $1.4 million, mostly from legacy ultrasound sales. To cover its costs, the company relies heavily on outside funding. In 2025, they raised about $9.5 million by selling preferred stock and warrants. For you, this means the company is spending cash quickly to fund operations. They are also issuing more shares, which reduces your ownership percentage in the company.

3. Major wins and challenges

• The Big Win: The February 2025 merger helped the company acquire new technology and expand its distribution network. This move aims to reduce reliance on older products and diversify income.
• The Challenge: The company has a complex financial structure. Because they have multiple classes of preferred stock and debt, preferred shareholders get paid first if the company is sold or goes bankrupt. This leaves less for common stockholders.

4. Financial health: Are they on solid ground?

The company requires high maintenance. As of June 2025, they held about $2.1 million in cash. This is not enough to fund operations for the next year without raising more money. They frequently sell stock to private investors to stay afloat. If you want a company with stable, predictable cash flow, this isn't it. They are in "startup mode," where managing cash is the main priority. With a public market value of about $7.3 million, this is a small, highly volatile stock.

5. Key risks: What could go wrong?

• Dilution: The company uses "pre-funded warrants." As these are used, the company issues more shares. This reduces the potential profit per share for existing investors.
• Customer Concentration: About 35% of revenue comes from a few distributors. Losing one major contract would significantly hurt the company’s total sales.
• Geopolitical Risk: With research and manufacturing in Israel, the company faces risks from regional instability. Conflict could disrupt supply chains or halt production.
• Nasdaq Compliance: The company has struggled to keep its stock price above the $1.00 minimum required by Nasdaq. Being removed from the exchange would make it harder to trade the stock and likely cause the price to drop.

6. Future outlook

The company is in "execution mode." Management is focused on integrating new technology and stabilizing the balance sheet. They do not expect to be profitable for the next 18 to 24 months. The focus remains on survival, growing sales, and getting FDA clearance for new products. Expect continued volatility and likely more share sales until the company can prove it can sustain itself.

Final Thought for Investors: ENvue Medical is currently a high-risk, speculative play. Because they are burning cash and relying on share sales to fund their operations, they are best suited for investors who are comfortable with significant volatility and the possibility of further dilution. If you prefer companies with established profits or predictable growth, you may want to look elsewhere. If you are interested in the potential of their new technology, keep a close eye on their cash balance and their ability to maintain their Nasdaq listing.